1 |
Karashima T, Sweeney P, Slaton JW et al : Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8 : 1253, 2002
|
2 |
Eisenhauser EA, Vermorken JB : The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55 : 5, 1998
DOI
ScienceOn
|
3 |
Robinson DR, Wu YM, Lin SF : The protein tyrosine kinase family of the human genome. Oncogene 19(49) : 5548, 2000
DOI
ScienceOn
|
4 |
Younes MN, Yigitbasi OG, Park YW et al : Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation. Cancer Res 65 : 4716, 2005
DOI
ScienceOn
|
5 |
Ullrich A, Schlessinger J : Signal transduction by receptors with tyrosine kinase activity. Cell 61 : 203, 1990
DOI
ScienceOn
|
6 |
Dassonville O, Formento JL, Francoual M et al : Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 : 1873, 1993
|
7 |
Mamot C, Drummond DC, Noble CO et al : Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65(24) : 11631, 2005
DOI
ScienceOn
|
8 |
Thaker PH, Yazici S, Nilsson MB et al : Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 11(13) : 4923, 2005
DOI
ScienceOn
|
9 |
Schrijvers D, Vermorken JB : Role of taxoid in head and neck cancer. Oncologist 5 : 199, 2005
DOI
ScienceOn
|
10 |
Yigitbasi OG, Younes MN, Doan D et al : Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64 : 7977, 2004
DOI
ScienceOn
|
11 |
Cunningham MP, Thomas H, Fan Z et al : Responses of human colorectal tumor cells to treatment with the antiepidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor Gefitinib. Cancer Res 66(15) : 7708, 2006
DOI
ScienceOn
|
12 |
Park YW, Lee JW, Kim SH : Expressions of metastasisrelated factors in orthotopic tumor models of oral squamous cell carcinoma. J Kor Assoc Maxillofac Plast Reconstr Surgeons 30(6) : 529, 2008
|
13 |
Park YW, Younes MN, Jasser SA et al: AEE788, a dual tyrosine kinase inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 11 : 1963, 2005
DOI
ScienceOn
|
14 |
Sano D, Myers JN : Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26 : 645, 2007
DOI
|
15 |
Pawson T : Protein modules and signalling networks. Nature 373(6515) : 573, 1995
DOI
PUBMED
ScienceOn
|
16 |
Marshall J : Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107 : 1207, 2006
DOI
PUBMED
ScienceOn
|
17 |
Yazici S, Kim SJ, Busby JE et al : Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate 65(3) : 203, 2005
DOI
ScienceOn
|
18 |
Ries LA, Miller BA, Hartman AM et al : Cancer statistics review 1973-1988. National Cancer Institute, NIH Publications no 91-2789
|
19 |
Kuwai T, Nakamura T, Sasaki et al : Phosphorylatd epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia 10(5) : 489, 2008
|
20 |
Kupferman ME, Myers JN : Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol Clin North Am 39(2) : 229, 2006
DOI
ScienceOn
|
21 |
Kim S, Prichard CN, Younes MN et al : Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Cancer Ther 12(2) : 600, 2006
DOI
ScienceOn
|
22 |
Choi S, Myers JN : Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 87(2) : 191, 2008
DOI
ScienceOn
|
23 |
Harari PM : Epidermal growth factor receptor inhibition strategies in oncology. Endoc Rel Cancer : 11 689, 2004
DOI
PUBMED
ScienceOn
|
24 |
Harding J, Burtness B : Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 41(2) : 107, 2005
DOI
ScienceOn
|
25 |
Kttner C : Paclitaxel administration along with antiangiogenic therapy in head and neck squamous cell carcinoma xenograft model. Int Poster J Dent Oral Med 3(4) : poster93, 2001
|
26 |
Zwick E, Bange Z, Ullrich A : Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8(3) : 161, 2001
DOI
ScienceOn
|
27 |
Sumitomo M, Asano T, Asakuma J et al : ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10(2) : 794, 2004
DOI
ScienceOn
|
28 |
Cohen S, Carpenter G, King L Jr : Epidermal growth factor receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255 : 1555, 1980
|